UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 6, 2016
AVEXIS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
001-37693 |
| 90-1038273 |
(Commission File No.) |
| (IRS Employer Identification No.) |
2275 Half Day Rd, Suite 160
Bannockburn, Illinois 60015
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (847) 572-8280
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On May 6, 2016, Jerry R. Mendell, MD, Director of the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital, presented an interim analysis of data as of April 1, 2016 from AveXis, Inc.’s (the “Company”) ongoing Phase 1 clinical trial of AVXS-101 for the treatment of spinal muscular atrophy Type 1 at the 19th Annual Meeting of the American Society of Gene & Cell Therapy in Washington, D.C. A copy of Dr. Mendell’s presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01 Other Events.
On May 6, 2016, the Company issued a press release announcing an interim analysis of data as of April 1, 2016 from its ongoing Phase 1 clinical trial of AVXS-101 for the treatment of spinal muscular atrophy Type 1. The full text of the Company’s press release regarding the announcement is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit |
|
|
Number |
| Exhibit Description |
99.1 |
| Presentation slides presented on May 6, 2016. |
|
|
|
99.2 |
| Press Release, dated May 6, 2016, titled “AveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 6, 2016 | AVEXIS, INC. | |
|
| |
|
| |
| By: | /s/ Sean P. Nolan |
|
| Sean P. Nolan |
|
| President and Chief Executive Officer |